New pill for Parkinson's? first safety tests begin
Disease control
Recruiting now
This early-stage study tests a new oral drug called HL-400 in 86 healthy volunteers aged 18 to 65. The drug aims to reduce inflammation linked to Parkinson's disease. The main goal is to check safety and how the drug moves through the body, not yet to treat the disease.
Phase: PHASE1 • Sponsor: Highlightll Pharmaceutical (USA) LLC • Aim: Disease control
Last updated May 22, 2026 13:52 UTC